V

Veru
D

VERU

1.04500
USD
-0.04
(-3.24%)
Market Closed
Volume
117,200
EPS
-0
Div Yield
-
P/E
-4
Market Cap
152,971,196
Related Instruments
    A
    AGEN
    -0.15000
    (-3.94%)
    3.66000 USD
    C
    CTMX
    -0.03040
    (-3.53%)
    0.83110 USD
    E
    ESPR
    0.05000
    (2.33%)
    2.20000 USD
    L
    LPCN
    0.02000
    (0.44%)
    4.59000 USD
    V
    VKTX
    1.170
    (3.56%)
    34.060 USD
    More
News

Title: Veru

Sector: Healthcare
Industry: Biotechnology
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.